Cryoablation vendor Endocare has received 510(k) clearance from the U.S. Food and Drug Administration to market its new Cryocare CN2 system.
The product utilizes nitrogen as the freezing and tumor-destroying element, according to the Irvine, CA-based vendor. Endocare believes nitrogen technology may drive more widespread adoption of cryoablation internationally, because in many countries nitrogen is more readily available and less expensive than argon.
The firm said that cryoablation is becoming a more common treatment option by urologists and interventional radiologists in the U.S. It said that approximately 3,700 prostate, renal, and other cancers were treated with cryoablation in the first six months of this year, compared with 1,600 procedures performed in 2001.
By AuntMinnie.com staff writers
September 12, 2006
Related Reading
Cryoablation provides effective palliation for bone metastasis, April 4, 2005
EndoCare to showcase Percryo probes, November 14, 2003
EndoCare brings Cryocare to market, August 21, 2003
Cryoablation for prostate cancer yields long-term success, December 4, 2002
Medicare to cover Endocare's cryosurgery prostate cancer treatment, December 13, 2000
Copyright © 2006 AuntMinnie.com